Cargando…
Reducing the rate of guideline-discordant therapy for inpatients with community-acquired pneumonia
Background: Despite guidelines recommending shorter durations of therapy and empiric coverage of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) only for patients with certain risk factors, optimizing therapy for community-acquired pneumonia (CAP) remains a challenge fo...
Autores principales: | Hannan, Kellie Arensman, Frykman, Paul, Mathiowetz, Eric, Sathre, Jill, Yang, Nou Cheng, Jensen, Kelsey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594197/ http://dx.doi.org/10.1017/ash.2023.244 |
Ejemplares similares
-
Electronic health record–based identification of inpatients receiving antibiotic treatment for community-acquired pneumonia
por: Yang, David, et al.
Publicado: (2023) -
Empiric antibiotic selection for community-acquired pneumonia in US hospitals, 2013–2020
por: Wolford, Hannah, et al.
Publicado: (2023) -
Validation of an electronic algorithm to identify appropriate antibiotic use for community-acquired pneumonia in children
por: Chiotos, Kathleen, et al.
Publicado: (2023) -
A little education goes a long way: Decreasing antibiotics for community-acquired pneumonia in COVID-19 patients
por: Tripathi, Ravi, et al.
Publicado: (2022) -
Risk Factors and outcomes associated with inappropriate empiric broad-spectrum antibiotic use in hospitalized patients with community-acquired pneumonia
por: Gandhi, Tejal, et al.
Publicado: (2023)